US 12,410,254 B2
Treatment of cardiometabolic disease with inhibitors of type I interferon signalling
Dominic Sinibaldi, Gaithersburg, MD (US); Wendy White, Gaithersburg, MD (US); Michael Smith, Gaithersburg, MD (US); Kerry Casey, Gaithersburg, MD (US); and Gabor Illei, Gaithersburg, MD (US)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Filed by ASTRAZENECA AB, Södertälje (SE)
Filed on Dec. 22, 2023, as Appl. No. 18/394,365.
Application 18/394,365 is a continuation of application No. 18/336,368, filed on Jun. 16, 2023, abandoned.
Application 18/336,368 is a continuation of application No. 17/999,257, abandoned, previously published as PCT/EP2021/064312, filed on May 28, 2021.
Claims priority of provisional application 63/031,854, filed on May 29, 2020.
Prior Publication US 2024/0158519 A1, May 16, 2024
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61P 9/10 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 9/10 (2018.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 11 Claims
 
1. A method of treating or reducing the risk for development of a cardiometabolic disease in a patient in need thereof, wherein the method comprises administering about 300 mg to about 1000 mg of an inhibitor of type I IFN signaling to the patient,
wherein the inhibitor is a human monoclonal antibody comprising
a) a heavy chain variable region complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 3;
b) a heavy chain variable region complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NO: 4;
c) a heavy chain variable region complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO: 5;
d) a light chain variable region complementarity determining region 1 (LCDR1) comprising the amino acid sequence SEQ ID NO: 6;
e) a light chain variable region complementarity determining region 2 (LCDR2) comprising the amino acid sequence SEQ ID NO: 7; and
f) a light chain variable region complementarity determining region 3 (LCDR3) comprising the amino acid sequence SEQ ID NO: 8, and
wherein the patient has systemic lupus erythematosus (SLE), and wherein the cardiometabolic disease is selected from the group consisting of premature atherosclerosis, myocarditis, arrhythmia, valvular dysfunction, vasculitis, aortitis, atherosclerosis, and coronary vasculitis;
wherein the inhibitor is administered to the patient intravenously; and
wherein the patient has high levels of expression of GlycA, TNF-α, and IL-10 compared to a healthy subject.